AR053226A1 - Combinaciones metodos y composiciones para tratar el cancer - Google Patents
Combinaciones metodos y composiciones para tratar el cancerInfo
- Publication number
- AR053226A1 AR053226A1 ARP060101515A ARP060101515A AR053226A1 AR 053226 A1 AR053226 A1 AR 053226A1 AR P060101515 A ARP060101515 A AR P060101515A AR P060101515 A ARP060101515 A AR P060101515A AR 053226 A1 AR053226 A1 AR 053226A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- bcr
- lower alkyl
- stem cell
- cytotoxic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 231100000433 cytotoxic Toxicity 0.000 abstract 3
- 230000001472 cytotoxic effect Effects 0.000 abstract 3
- 210000000130 stem cell Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 2-chloro-6-methylphenyl Chemical group 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- VVOYROSONSLQQK-UHFFFAOYSA-N 3-[2-[2-cyclopentyl-6-(4-dimethylphosphorylanilino)purin-9-yl]ethyl]phenol Chemical compound C1=CC(P(C)(=O)C)=CC=C1NC1=NC(C2CCCC2)=NC2=C1N=CN2CCC1=CC=CC(O)=C1 VVOYROSONSLQQK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 abstract 1
- 229960003736 bosutinib Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 abstract 1
- 229950009919 saracatinib Drugs 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una combinacion del inhibidor BCR-ABL, ejemplificado por 'N-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil)-2-metil-4-pirimidin)amino)-5-tiazolcarboxamida y/u otros inhibidores BCR/AB, y un citotoxico selectivo de célula madre, ejemplificado por sal de clorohidrato de ( R )-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(fenilmetil)-4-(2-tienilsulfonil)-1H-1,4-benzodiazepin-7-carbonitrilo, y otros agentes citotoxicos de célula madre, composiciones farmacéuticas de la combinacion y métodos para usar las composiciones farmacéuticas en el tratamiento de trastornos oncologicos. Reivindicacion 2: El método de conformidad con la reivindicacion 1, caracterizado porque el agente citotoxico selectivo de célula madre es un compuesto de formula (3) o una sal farmacéuticamente aceptable del mismo en donde R1 es Cl, Br, CN, fenilo opcionalmente sustituido, 2-,3- o 4-piridilo opcionalmente sustituido; R2 es alquilo inferior opcionalmente sustituido, o aralquilo opcionalmente sustituid; R3 y R5 son cada uno independientemente alquilo inferior opcionalmente sustituido, arilo opcionalmente sustituido, o heterociclo opcionalmente sustituido; R4 es H o alquilo inferior; Z1 es CO, SO2, CO2 o SO2N(R5)-; y n es 1 o 2. Reivindicacion 4: El método para tratar el cáncer de conformidad con la reivindicacion 2, caracterizado porque el inhibidor BCR/ABL se selecciona del compuesto de formula (1) imatinib, AMN-107, SKI 606, AZD0530, y AP23464, o una sal o hidrato farmacéuticamente aceptable de los mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67074405P | 2005-04-13 | 2005-04-13 | |
| US74843305P | 2005-12-08 | 2005-12-08 | |
| US90250206A | 2006-04-12 | 2006-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053226A1 true AR053226A1 (es) | 2007-04-25 |
Family
ID=38006649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101515A AR053226A1 (es) | 2005-04-13 | 2006-04-17 | Combinaciones metodos y composiciones para tratar el cancer |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR053226A1 (es) |
-
2006
- 2006-04-17 AR ARP060101515A patent/AR053226A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075087L (no) | Kombinasjoner, metoder og sammensetninger for behandling av cancer | |
| PE20070768A1 (es) | Derivados de fenil-1,2,4-oxadiazolona con grupo fenilo, procedimientos para su preparacion | |
| PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| ATE481093T1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| NO20075154L (no) | Formuleringer av en src/abl-inhibitor | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| NO20091892L (no) | Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre | |
| ATE450532T1 (de) | Pyridinyl- oder pyrimidinylthiazole mit proteinkinasehemmender wirkung | |
| PE20091656A1 (es) | Compuestos heterociclicos como inhibidores de la cinasa raf | |
| NO20051826L (no) | Heterosyklisk substituerte piperaziner for behandling av schizofreni | |
| NO20071320L (no) | Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer. | |
| PE20091974A1 (es) | Derivados de indazoles sustituidos con fenil o piridinilo | |
| PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
| TW200518750A (en) | Cornea-conjunctiva disorder treating agent | |
| PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
| ATE423105T1 (de) | Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd | |
| PE20061394A1 (es) | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas | |
| PE20070359A1 (es) | Inhibidores de pirimidinilpirazol de aurora quinasas | |
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
| DK1926729T3 (da) | Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander | |
| NO20084674L (no) | 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser | |
| PE20091617A1 (es) | Tiazolil-dihidro-indazoles | |
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| AR053226A1 (es) | Combinaciones metodos y composiciones para tratar el cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |